TY - JOUR
T1 - Bacterial membrane vesicles as promising vaccine candidates
AU - Jiang, Linglei
AU - Schinkel, Michelle
AU - van Essen, Max
AU - Schiffelers, Raymond M
N1 - Funding Information:
LJ acknowledges financial support from the China Scholarship Council (CSC). Prof. Rob Willems (Department of Medical Microbiology, UMC Utrecht) is acknowledged for giving suggestions for this manuscript. Prof. Joen Luirink (Faculty of Science, Molecular Microbiology, Vrije Universiteit Amsterdam) is acknowledged for discussion on the work he has published.
Funding Information:
LJ acknowledges financial support from the China Scholarship Council (CSC). Prof. Rob Willems (Department of Medical Microbiology, UMC Utrecht) is acknowledged for giving suggestions for this manuscript. Prof. Joen Luirink (Faculty of Science, Molecular Microbiology, Vrije Universiteit Amsterdam) is acknowledged for discussion on the work he has published.
Publisher Copyright:
© 2019
PY - 2019/12
Y1 - 2019/12
N2 - Both Gram-positive and Gram-negative bacteria can release nano-sized lipid bilayered structures, known as membrane vesicles (MVs). These MVs play an important role in bacterial survival by orchestrating interactions between bacteria and between bacteria and host. The major constituents of MVs are proteins, lipids and nucleic acids. Due to the immunogenicity of the membrane lipids and/or proteins of the MVs, in combination with adjuvant danger signals and the repeating patterns on the nanosized surface, MVs can effectively stimulate the innate and adaptive immune system. Since they are non-replicating, they are safer than attenuated vaccines. In addition, by genetic engineering of the donor cells, further improvements to their safety profile, immunogenicity and yield can be achieved. To date, one MV-based vaccine against Neisseria meningitidis (N. meningitidis) serogroup B was approved. Other (engineered) MVs in the pipeline study are mostly in the preclinical phase.
AB - Both Gram-positive and Gram-negative bacteria can release nano-sized lipid bilayered structures, known as membrane vesicles (MVs). These MVs play an important role in bacterial survival by orchestrating interactions between bacteria and between bacteria and host. The major constituents of MVs are proteins, lipids and nucleic acids. Due to the immunogenicity of the membrane lipids and/or proteins of the MVs, in combination with adjuvant danger signals and the repeating patterns on the nanosized surface, MVs can effectively stimulate the innate and adaptive immune system. Since they are non-replicating, they are safer than attenuated vaccines. In addition, by genetic engineering of the donor cells, further improvements to their safety profile, immunogenicity and yield can be achieved. To date, one MV-based vaccine against Neisseria meningitidis (N. meningitidis) serogroup B was approved. Other (engineered) MVs in the pipeline study are mostly in the preclinical phase.
KW - Adaptive Immunity/immunology
KW - Adjuvants, Immunologic
KW - Animals
KW - Antibody Formation/immunology
KW - Bacteria/immunology
KW - Bacterial Proteins/immunology
KW - Humans
KW - Lipid Bilayers/immunology
KW - Membrane Lipids/immunology
KW - Membranes/immunology
KW - Vaccines/immunology
UR - http://www.scopus.com/inward/record.url?scp=85073224524&partnerID=8YFLogxK
U2 - 10.1016/j.ejpb.2019.09.021
DO - 10.1016/j.ejpb.2019.09.021
M3 - Review article
C2 - 31560955
SN - 0939-6411
VL - 145
SP - 1
EP - 6
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
ER -